Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: Relationship to alcohol withdrawal symptoms

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 334-342

  Anton, Raymond F ^a   Myrick, Hugh ^a,b   Baros, Alicia M ^a   Latham, Patricia K ^a   Randall, Patrick K ^a   Wright, Tara M ^a,b   Stewart, Scott H ^a   Waid, Randy ^a   Malcolm, Robert ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alcohol withdrawal; Alcoholism; Flumazenil; Gabapentin; Treatment

Indexed keywords

CARBOHYDRATE; FLUMAZENIL; GABAPENTIN; PLACEBO; TRANSFERRIN;

ADULT; AGITATION; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SLEEP PARAMETERS; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ALCOHOL DRINKING; ALCOHOLISM; AMINES; CYCLOHEXANECARBOXYLIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUMAZENIL; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SELECTION; SLEEP; SUBSTANCE WITHDRAWAL SYNDROME; TEMPERANCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 68449090139     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181aba6a4     Document Type: Article

References (48)

1. Becker HC. Alcohol dependence, withdrawal and relapse. Alcohol Res Health. 2008;31:348-361.
2. Cagetti E, Liang J, Spigelman I, et al. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol. 2003;63:53-64.
3. Olsen RW, Liang J, Cagetti E, et al. Plasticity of GABAA receptors in brains of rats treated with chronic intermittent ethanol. Neurochem Res. 2005;30:1579-1588.
4. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World. 1998;22:13-24.
5. Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res. 2004;28:1137-1144.
6. Buck KJ, Heim H, Harris RA. Reversal of alcohol dependence and tolerance by a single administration of flumazenil. J Pharmacol ExpTher. 1991;257:984-989.
7. File SE, Baldwin HA, Hitchcott PK. Flumazenil but not nitrendipine reverses the increased anxiety during ethanol withdrawal in the rat. Psychopharmacology (Berl). 1989;98:262-264.
8. Knapp DJ, Overstreet DH, Moy SS, et al. SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol. 2004;32:101-111.
9. Nutt D, Glue P, Wilson S, et al. Flumazenil in alcohol withdrawal. Alcohol Alcohol Suppl. 1993;2:337-341.
10. Potokar J, Coupland N, Glue P, et al. Flumazenil in alcohol withdrawal: a double-blind placebo-controlled study. Alcohol Alcohol. 1997;32:605-611.
11. Adinoff B, Majchrowicz E, Martin PR, et al. The benzodiazepine antagonist Ro 15-1788 does not antagonize the ethanol withdrawal syndrome. Biol Psychiatry. 1986;21:643-649.
12. Gerra GCR, Volpi R, Maninetti L, et al. Effectiveness of flumazenil in the treatment of alcohol withdrawal. Curr Ther Res Clin Exp. 1991;50:62-66.
13. Sanna E, Mostallino MC, Busonero F, et al. Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal. J Neurosci. 2003;23:11711-11724.
14. Biggio F, Gorini G, Caria S, et al. Flumazenil selectively prevents the increase in alpha(4)-subunit gene expression and an associated change in GABA(A) receptor function induced by ethanol withdrawal. J Neurochem. 2007;102:657-666.
15. Smith SS, Gong QH, Hsu FC, et al. GABAA receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature. 1998;392:926-930.
16. Cho SW, Cho EH, Choi SY. Activation of two types of brain glutamate dehydrogenase isoproteins by gabapentin. FEBS Lett. 1998;426:196-200.
17. Kelly KM, Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 1998;38:139-144.
18. Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypothesis of gabapentin pharmacology. Epilepsy Res. 1998;29:233-249.
19. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol. 1996;39:95-99.
20. Bonnet U, Banger M, Leweke FM, et al. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32:107-109.
21. Watson WP, Robinson E, Little HI The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropsychopharmacology. 1997;36:1369-1375.
22. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413.
23. Myrick H, Malcolm R, Brady K. Gabapentin treatment of alcohol withdrawal. Am J Psychiatry. 1998;155:1626.
24. Bozikas V, Petrikis P, Gamvrula K, et al. Treatment of alcohol withdrawal with gabapentin. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:197-199.
25. Voris J, Smith NL, Rao SM, et al. Gabapentin for the treatment of ethanol withdrawal. Subst Abus. 2003;24:129-132.
26. Mariani JJ, Rosenthal RN, Tross S, et al. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15:76-84.
27. Bisaga A, Evans SM. The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend. 2006;83:25-32.
28. Myrick H, Anton R, Voronin K, et al. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res. 2007;31:221-227.
29. Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57:542-544.
30. Brower KJ, Kim HM, Strobbe S, et al. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32:1429-1438.
31. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68:1691-1700.
32. Roberto M, Gilpin NW, O'Dell LE, et al. Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci. 2008;28:5762-5771.
33. Urschel HC, Hanselka LL, Gromov IL, et al. Open-label study of a proprietary treatment program targeting type A γaminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc. 2007;82:1170-1178.
34. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ, eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992:41-72.
35. Skinner HA, Horn JL. Alcohol Dependence Scale: Users Guide. Toronto, Canada: Addiction Research Foundation; 1984.
36. Anton RF, Moak DH, Latham P. The Obsessive-Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19:92-99.
37. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, CA: Educational & Industrial Testing Service; 1971.
38. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
39. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193-213.
40. Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297-307.
41. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357.
42. Anton RF, Dominick C, Bigelow M, et al. Comparison of Bio-Rad %CDT TIA and CDTect as laboratory markers of heavy alcohol use and their relationships with gamma-glutamytransferase. Clin Chem. 2001;47:1769-1775.
43. Miller WR. Combined Behavioral Intervention Manual: A Clinical Research Guide for Therapists Treating People With Alcohol Abuse and Dependence. Vol 1. Bethesda, MD: DHHS; 2004. Pub. No. (NIH) 04-5288.
44. Longabaugh R, Zweben A, Locastro JS, et al. Origins, issues and options in the development of the combined behavioral intervention. J Stud Alcohol Suppl. July 2005;(15):179-187.
45. Hall W, Zador D. The alcohol withdrawal syndrome. Lancet. 1997;349:1897-1900.
46. Moak DH, Anton RF, Malcolm R, et al. Alcoholic subjects with anxiety disorder: characteristics of completers and noncompleters in a pharmacologic study. Am J Addict. 1993;2:39-47.
47. Follesa P, Mancuso L, Biggio F, et al. Gamma-hydroxybutyric acid and diazepam antagonize a rapid increase in GABA(A) receptors alpha(4) subunit mRNA abundance induced by ethanol withdrawal in cerebellar granule cells. Mol Pharmacol. 2003;63:896-907.
48. Follesa P, Cagetti E, Mancuso L, et al. Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res Mol Brain Res. 2001;92:138-148.